XML 54 R43.htm IDEA: XBRL DOCUMENT v3.25.3
Note 8 - Segment Reporting - Reconciliation of Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Product revenue $ 86 $ 0 $ 86 $ 0
Adjusted cost of product revenue 279 0 279 0
Total other income, net 982 975 3,338 1,796
Net loss (19,385) (12,680) (55,348) (34,200)
Operating Segments [Member]        
Product revenue 86 0 86 0
Adjusted cost of product revenue [1] 172 0 172 0
Cross platform research and engineering [2] 3,546 3,084 11,133 9,586
R&D manufacturing and engineering [3] 2,328 1,376 6,658 3,498
Clinical and regulatory [4] 2,363 1,245 5,902 2,913
General and administrative [5] 3,993 3,861 11,611 10,378
Sales and marketing [6] 2,177 813 5,997 1,937
Other segment items [7] 5,874 3,276 17,299 7,684
Total other income, net (982) (975) (3,338) (1,796)
Net loss $ (19,385) $ (12,680) $ (55,348) $ (34,200)
[1] Adjusted cost of product revenue includes material costs, cash compensation costs, fees paid to consultants and outside service providers and organizations, and other expenses relating to manufacturing the Company’s commercial products. It does not include stock-based compensation, depreciation, or amortization - see Other Segment Items described in footnote 7 below.
[2] Cross platform research and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, prototype spending and other expenses relating to the acquisition, design and development of the Company’s clinical stage devices.
[3] R&D manufacturing and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with the procurement of materials and the manufacturing of the Company’s clinical stage devices.
[4] Clinical and regulatory includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with clinical trials and regulatory approvals required for the development of the Company’s clinical stage devices.
[5] General and administrative includes compensation costs and fees paid to consultants and outside service providers and organizations in support of the administrative functions of the Company, including finance, legal, human resources, IT and facilities.
[6] Sales and marketing includes compensation costs, fees paid to consultants and outside service providers and organizations, costs associated with marketing and sales strategy as well as execution of marketing and sales initiatives for the Company's products.
[7] Other segment items includes stock-based compensation, depreciation and amortization.